Burgess B. Freeman

Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acid

Tandem Duplications in <i>UBTF</i> Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency

Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy

Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk

MODL-06. Targeting c-MET in combination with radiation is effective in MET-fusion driven high-grade glioma

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma

Modeling and targeting of erythroleukemia by hematopoietic genome editing

Identification of small molecules that mitigate vincristine‐induced neurotoxicity while sensitizing leukemia cells to vincristine

Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine

Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses

Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy

Establishing a Preclinical Multidisciplinary Board for Brain Tumors

Orthotopic patient-derived xenografts of paediatric solid tumours

Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study

Targeting the DNA Repair Pathway in Ewing Sarcoma

Pemetrexed and Gemcitabine as Combination Therapy for the Treatment of Group3 Medulloblastoma

Pharmacokinetics and Efficacy of the Spleen Tyrosine Kinase Inhibitor R406 after Ocular Delivery for Retinoblastoma